



8 June 2012

## **Universal Biosensors delivers on first development milestone with Siemens**

Universal Biosensors (ASX:UBI) announced today that it has delivered on its first developmental milestone in its collaboration with Siemens Healthcare Diagnostics to help Siemens commercialise a range of novel handheld analyzers for the point-of-care coagulation testing market.

The first milestone, which relates to proof of technical feasibility of a new test strip, has been achieved on schedule and on budget. Universal Biosensors will receive US\$1.5 million as consideration for this milestone, bringing the total payments from Siemens to date to US\$4.5 million.

Under the agreement, commenced in September 2011, Universal Biosensors will develop a range of test strips and reader products in collaboration with and exclusively for Siemens. In turn, Siemens contributes to development costs through the US\$3M up-front fee as well as a series of six milestone payments, due when Universal Biosensors achieves its specified deliverables.

The first product, expected to be launched in 2013, is a version of Universal Biosensors' point-of-care PT-INR test (used to monitor the application of the anti-coagulant therapy, Warfarin). The new test strip, which has passed technical feasibility in this development milestone, will form the basis of a future product to be commercialised by Siemens following the launch of the PT-INR test.

Paul Wright, CEO of Universal Biosensors said: "Delivering on this first, challenging milestone on time and on budget is an important step forward in our collaboration with Siemens and demonstrates the strength of our research and development capabilities".

"The point-of-care coagulation testing market is large and growing. Our technology is breaking new ground in this space and Siemens is the perfect partner organisation to commercialise coagulation products in this global market."

Point-of-care coagulation testing is estimated to be worth over US\$1billion annually and is growing at over 10% per year. Universal Biosensors and Siemens are focused on offering new coagulation technologies that deliver laboratory-quality results at the point-of-care in response to growing demand for near-patient testing solutions, including those that deliver time-critical coagulation data.

**Ends**

### *Enquiries:*

Paul Wright +61 3 9213 9000

### **About Universal Biosensors**

For additional information in relation to Universal Biosensors, refer to <http://www.universalbiosensors.com/announcements.html>.

Universal Biosensors Pty Ltd  
ABN 35 098 234 309

1 Corporate Avenue  
Rowville VIC 3178  
Australia

Telephone +61 3 9213 9000  
Facsimile +61 3 9213 9099  
Email [secretary@universalbiosensors.com](mailto:secretary@universalbiosensors.com)  
[www.universalbiosensors.com](http://www.universalbiosensors.com)



**Universal Biosensors**

Universal Biosensors is a specialist medical diagnostics company, founded in 2001, that is focused on the development, manufacture and commercialisation of a range of in vitro diagnostic tests for point-of-care use. These tests capitalise on a technology platform which uses a novel electrochemical cell that can be adapted for multiple analytes and provide for enhanced measurements in whole blood.

### **Forward-Looking Statements**

The statements contained in this release that are not purely historical are forward-looking statements within the meaning of the Exchange Act. Forward-looking statements in this release include statements regarding our expectations, beliefs, hopes, intentions or strategies regarding the proposed offering. All forward-looking statements included in this release are based upon information available to us as of the date hereof, and we assume no obligation to update any such forward-looking statement as a result of new information, future events or otherwise. Our actual results could differ materially from our current expectations. We cannot assure you when, if at all, the proposed offering will occur, and the terms of any such offering are subject to change. Factors that could cause or contribute to such differences include, but are not limited to, factors and risks disclosed from time to time in reports filed with the SEC.